Publication | Closed Access

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

Advanced CancerOncologyPancreatic CancerMedicinePathologyPharmacotherapyAnti-cancer AgentCancer TreatmentGemcitabine-containing CombinationPharmacologyCancer Research